Eli Lilly and Company $LLY Shares Sold by Providence Wealth Advisors LLC

Providence Wealth Advisors LLC cut its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 0.8% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 12,661 shares of the company’s stock after selling 98 shares during the period. Eli Lilly and Company accounts for about 6.8% of Providence Wealth Advisors LLC’s holdings, making the stock its 3rd biggest position. Providence Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $9,870,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Lazard Freres Gestion S.A.S. raised its stake in shares of Eli Lilly and Company by 114.3% during the 2nd quarter. Lazard Freres Gestion S.A.S. now owns 77,295 shares of the company’s stock worth $60,253,000 after buying an additional 41,222 shares in the last quarter. Precedent Wealth Partners LLC grew its holdings in Eli Lilly and Company by 15.3% during the second quarter. Precedent Wealth Partners LLC now owns 294 shares of the company’s stock worth $229,000 after acquiring an additional 39 shares during the period. Capital Advisors Inc. OK raised its position in Eli Lilly and Company by 6.8% in the second quarter. Capital Advisors Inc. OK now owns 6,747 shares of the company’s stock worth $5,260,000 after acquiring an additional 429 shares in the last quarter. Family CFO Inc acquired a new stake in Eli Lilly and Company in the second quarter valued at $54,000. Finally, Duquesne Family Office LLC boosted its position in shares of Eli Lilly and Company by 52.5% during the 1st quarter. Duquesne Family Office LLC now owns 94,830 shares of the company’s stock worth $78,321,000 after purchasing an additional 32,640 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on LLY. Morgan Stanley increased their price target on shares of Eli Lilly and Company from $1,090.00 to $1,171.00 and gave the company an “overweight” rating in a report on Thursday, November 13th. Leerink Partnrs raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Monday, November 10th. The Goldman Sachs Group lifted their price target on shares of Eli Lilly and Company from $876.00 to $879.00 and gave the company a “buy” rating in a research report on Friday, October 10th. Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Tuesday, October 14th. Finally, Cantor Fitzgerald lifted their price objective on Eli Lilly and Company from $925.00 to $985.00 and gave the stock an “overweight” rating in a report on Friday, October 31st. Three analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and seven have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,027.95.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $1,058.05 on Friday. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,066.65. The business has a fifty day moving average of $855.89 and a 200-day moving average of $787.74. The stock has a market cap of $1.00 trillion, a price-to-earnings ratio of 69.15, a price-to-earnings-growth ratio of 1.21 and a beta of 0.43.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, October 30th. The company reported $7.02 EPS for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. During the same quarter last year, the business posted $1.18 EPS. The firm’s quarterly revenue was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be given a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, November 14th. Eli Lilly and Company’s payout ratio is currently 29.35%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.